Shanghai Lanyee Pharmaceutical Technology Co., Ltd

Bridging the Gap from

CMC Excellence to Clinical

Value

An integrated platform designed to de-risk biologics and accelerate the path to registrational studies.

CMC-TO-CLINICAL ACCELERATOR

12 Months

PCC to IND

>8 g/L

EA5 Cell Line Titer

180 mg/mL

SC Formulation

>80%

Recovery Rate

Our Mission

De-Risking the Path to Market through integrated technological platforms

Research & Development Pipeline

Complement and Thyroid Core Assets Advancing with Clear Differentiation

Key Update

EA5, as our core clinical asset, has completed pivotal registration preparation for PNH indication, targeting commercialization by 2028.

Leading Program

EA5: Long-Acting Subcutaneous Anti-C5 Antibody

Pipeline-in-a-Product across complement-mediated diseases

Clinical Performance

Rapid onset and durable C5 suppression with biomarker-guided dosing.
Patient Convenience

High-concentration SC formulation, injector-friendly for at-home administration.
CMC Advantages

High expression, low viscosity, scalable process with robust quality.
Commercial Positioning

Switch-friendly profile, designed for broad global partnering.

CLINICAL VALIDATION (PNH)

Platform Technology Solution

Molecular design guided by CMC developability and clinical end-points. Accelerating best-in-class biologics from discovery toclinical validation.

AI-assisted Antibody Engineering:

Our core competitive advantage is our unique ability to significantly de-risk and accelerate the development of high-quality drug candidates. We achieve this by integrating our three powerful technological platforms:
Predictive Developability Assessment (PDAP):

Critical early-stage screening to mitigate clinical and manufacturing risks.
Process Development & Industrialization:

Leveraging multinational pharma expertise to ensure robust, scalable, and cost-efficient production from day one.

Leadership Team

Deep expertise in CMC development, clinical operations, and biotechmanagement

Chao Zhuang, PhD

Founder and Chief Executive Officer of Neathera. Dr. Zhuang leads the company’s corporate strategy, financing, CMC, and strategic partnerships.
Liming Yang, PhD

Co-founder and Chief Operating Officer of Neathera. Dr. Yang is responsible for overseeing portfolio governance, resource allocation, and cross-functional execution.

Partner With Us

We are advancing differentiated biologics with global partnering potential. Contact us to explore collaboration opportunities.

Company Name：Neathera Inc.

Email：info@neathera.com

CONTACT US

NAVIGATION